Article
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
The Lancet. Respiratory medicine - 1 Nov 2020
Wu Yi-Long, Cheng Ying, Zhou Jianying, Lu Shun, Zhang Yiping, Zhao Jun, Kim Dong-Wan, Soo Ross Andrew, Kim Sang-We, Pan Hongming, Chen Yuh-Min, Chian Chih-Feng, Liu Xiaoqing, Tan Daniel Shao Weng, Bruns Rolf, Straub Josef, Johne Andreas, Scheele Jürgen, Park Keunchil, Yang James Chih-Hsin
Abstract excerpt
BACKGROUND: We evaluated the efficacy and safety of tepotinib, a potent and highly selective oral MET inhibitor, plus gefitinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) with MET overexpression (immunohistochemistry [IHC]2+ or IHC3+) or MET amplification having acquired resistance to EGFR inhibition. METHODS: In this open-label, phase 1b/2, multicentre,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.